Decoy Therapeutics, Inc. (DCOY)
2.69
-0.19
(-6.60%)
USD |
NASDAQ |
Sep 04, 16:00
2.74
+0.05
(+1.86%)
After-Hours: 20:00
Decoy Therapeutics Research and Development Expense (Quarterly) : 1.304M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.304M |
| March 31, 2026 | 0.7498M |
| December 31, 2025 | 0.1144M |
| September 30, 2025 | 0.0618M |
| June 30, 2025 | 0.1164M |
| March 31, 2025 | 0.0755M |
| December 31, 2024 | 0.1753M |
| September 30, 2024 | 0.1372M |
| June 30, 2024 | 0.2144M |
| March 31, 2024 | 0.243M |
| December 31, 2023 | 0.06M |
| September 30, 2023 | 1.036M |
| June 30, 2023 | 2.352M |
| March 31, 2023 | 3.726M |
| December 31, 2022 | 4.686M |
| September 30, 2022 | 3.790M |
| June 30, 2022 | 2.922M |
| December 31, 2021 | 2.696M |
| September 30, 2021 | 2.016M |
| June 30, 2021 | 2.096M |
| March 31, 2021 | 1.741M |
| December 31, 2020 | 2.024M |
| September 30, 2020 | 1.804M |
| June 30, 2020 | 1.443M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.643M |
| December 31, 2019 | 1.338M |
| September 30, 2019 | 1.141M |
| June 30, 2019 | 0.8401M |
| March 31, 2019 | 0.6999M |
| December 31, 2018 | 0.4838M |
| September 30, 2018 | 0.3536M |
| June 30, 2018 | 5.471M |
| March 31, 2018 | 4.680M |
| December 31, 2017 | 4.259M |
| September 30, 2017 | 4.739M |
| June 30, 2017 | 4.076M |
| March 31, 2017 | 3.915M |
| December 31, 2016 | 4.231M |
| September 30, 2016 | 5.665M |
| June 30, 2016 | 6.095M |
| March 31, 2016 | 4.387M |
| December 31, 2015 | 3.309M |
| September 30, 2015 | 3.445M |
| June 30, 2015 | 3.190M |
| March 31, 2015 | 2.805M |
| December 31, 2014 | 1.965M |
| September 30, 2014 | 0.9091M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Palatin Technologies, Inc. | 3.517M |
| Unicycive Therapeutics, Inc. | 2.788M |
| Nuvectis Pharma, Inc. | 4.684M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |